Aim Immunotech Stock Performance
| AIM Stock | USD 1.25 0.46 58.23% |
On a scale of 0 to 100, AIM ImmunoTech holds a performance score of 2. The firm shows a Beta (market volatility) of 1.54, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AIM ImmunoTech will likely underperform. Please check AIM ImmunoTech's total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether AIM ImmunoTech's price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AIM ImmunoTech are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, AIM ImmunoTech displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1031:1000 | Dividend Date 2019-06-11 | Last Split Date 2026-02-10 |
1 | AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical... | 11/18/2025 |
2 | AIM ImmunoTech Announces Stock Dividend | 12/30/2025 |
3 | Is AIM ImmunoTech Stock Outpacing Its Medical Peers This Year | 01/08/2026 |
4 | Acquisition by Bryan Nancy of 22645 shares of AIM ImmunoTech at 0.23 subject to Rule 16b-3 | 01/22/2026 |
5 | AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering | 01/23/2026 |
6 | Blend Named a Leader in AIM Researchs PeMa Quadrant Top Data Science Service Providers 2025 | 02/02/2026 |
7 | Longstanding AIM Mail Center Franchisee Renews Commitment to Serving Lake Wylie, South Carolina and Names Daughter as Co-Owner | 02/05/2026 |
8 | Little Excitement Around Ai-Media Technologies Limiteds Revenues As Shares Take 30 percent Pounding | 02/06/2026 |
9 | AIM ImmunoTech Announces Commencement of Rights Offering | 02/11/2026 |
10 | Why AI Captioning Is Gaining Attention on the ASX Stock Market | 02/12/2026 |
| Begin Period Cash Flow | 5.4 M | |
| Total Cashflows From Investing Activities | 4.7 M |
AIM ImmunoTech Relative Risk vs. Return Landscape
If you would invest 133.00 in AIM ImmunoTech on November 18, 2025 and sell it today you would lose (8.00) from holding AIM ImmunoTech or give up 6.02% of portfolio value over 90 days. AIM ImmunoTech is generating 0.2828% of daily returns assuming volatility of 9.6214% on return distribution over 90 days investment horizon. In other words, 86% of stocks are less volatile than AIM, and above 95% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
AIM ImmunoTech Target Price Odds to finish over Current Price
The tendency of AIM Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.25 | 90 days | 1.25 | about 62.27 |
Based on a normal probability distribution, the odds of AIM ImmunoTech to move above the current price in 90 days from now is about 62.27 (This AIM ImmunoTech probability density function shows the probability of AIM Stock to fall within a particular range of prices over 90 days) .
AIM ImmunoTech Price Density |
| Price |
Predictive Modules for AIM ImmunoTech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AIM ImmunoTech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.AIM ImmunoTech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. AIM ImmunoTech is not an exception. The market had few large corrections towards the AIM ImmunoTech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AIM ImmunoTech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AIM ImmunoTech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.08 | |
β | Beta against Dow Jones | 1.54 | |
σ | Overall volatility | 0.16 | |
Ir | Information ratio | -0.0048 |
AIM ImmunoTech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AIM ImmunoTech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AIM ImmunoTech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| AIM ImmunoTech had very high historical volatility over the last 90 days | |
| AIM ImmunoTech may become a speculative penny stock | |
| AIM ImmunoTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 170 K. Reported Net Loss for the year was (17.32 M) with profit before taxes, overhead, and interest of 17 K. | |
| AIM ImmunoTech has about 1.7 M in cash with (14.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Latest headline from kalkinemedia.com: Why AI Captioning Is Gaining Attention on the ASX Stock Market |
AIM ImmunoTech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AIM Stock often depends not only on the future outlook of the current and potential AIM ImmunoTech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AIM ImmunoTech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.5 M | |
| Cash And Short Term Investments | 4 M |
AIM ImmunoTech Fundamentals Growth
AIM Stock prices reflect investors' perceptions of the future prospects and financial health of AIM ImmunoTech, and AIM ImmunoTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AIM Stock performance.
| Return On Equity | -31.39 | ||||
| Return On Asset | -0.95 | ||||
| Operating Margin | (94.12) % | ||||
| Current Valuation | 4.18 M | ||||
| Shares Outstanding | 3.4 M | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 2.72 X | ||||
| Price To Sales | 37.99 X | ||||
| Revenue | 170 K | ||||
| Gross Profit | 17 K | ||||
| EBITDA | (16.49 M) | ||||
| Net Income | (17.32 M) | ||||
| Cash And Equivalents | 1.7 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 2.94 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.21 X | ||||
| Book Value Per Share | (2.20) X | ||||
| Cash Flow From Operations | (14.89 M) | ||||
| Earnings Per Share | (18.16) X | ||||
| Market Capitalization | 4.25 M | ||||
| Total Asset | 8.61 M | ||||
| Retained Earnings | (426.83 M) | ||||
| Working Capital | (5.36 M) | ||||
| Current Asset | 15.73 M | ||||
| Current Liabilities | 6.65 M | ||||
About AIM ImmunoTech Performance
By examining AIM ImmunoTech's fundamental ratios, stakeholders can obtain critical insights into AIM ImmunoTech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AIM ImmunoTech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3 K | -2.9 K | |
| Return On Tangible Assets | (3.31) | (3.15) | |
| Return On Capital Employed | 19.20 | 20.16 | |
| Return On Assets | (2.31) | (2.20) | |
| Return On Equity | 11.79 | 12.38 |
Things to note about AIM ImmunoTech performance evaluation
Checking the ongoing alerts about AIM ImmunoTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AIM ImmunoTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AIM ImmunoTech had very high historical volatility over the last 90 days | |
| AIM ImmunoTech may become a speculative penny stock | |
| AIM ImmunoTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 170 K. Reported Net Loss for the year was (17.32 M) with profit before taxes, overhead, and interest of 17 K. | |
| AIM ImmunoTech has about 1.7 M in cash with (14.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Latest headline from kalkinemedia.com: Why AI Captioning Is Gaining Attention on the ASX Stock Market |
- Analyzing AIM ImmunoTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AIM ImmunoTech's stock is overvalued or undervalued compared to its peers.
- Examining AIM ImmunoTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AIM ImmunoTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AIM ImmunoTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AIM ImmunoTech's stock. These opinions can provide insight into AIM ImmunoTech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (18.16) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.